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to the prostate and, thus, prostatic neoplasm. The use of magnetic res- 
onance imaging (MRI), the use of urethrogram combined with CT, or 
dynamic urethrography, may be alternatives to the definition of the in- 
ferior portion of the prostate, and we agree with Roach that further 
investigations would be beneficial. 
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VASOACIWITY, A POTENTIALLY IMPORTANT VARIABLE 
IN THE SEQUENCING OF TIRAPAZAMINE (SR 4233) 
AND RADIATION 
To the Editor: In their article describing the time course of tumor 
reoxygenation following tirapazamine (SR 4233, 3-amino 1,2,4-benzo- 
triazine- I,4 dioxide), Kim and Brown ( 10) suggest that “maximum in- 
teraction” between the drug and radiation should occur when the former 
is administered at some point prior to irradiation. However, it would 
appear that further data on the vasoactive properties of tirapazamine are 
needed before the most appropriate time for tirapazamine administration 
can be determined for clinical studies. 
Conventional chemotherapeutic agents such as mitomycin C and 
doxorubicin can markedly alter tumor blood flow and modulate hypoxia 
(8). Such alterations may be significant when chemotherapy is combined 
with irradiation. It has been postulated that the inferior local tumor 
control seen in patients with cervical tumors who were treated with the 
radiosensitizer pimonidazole (1 I) could have been due to the increase 
in tumor hypoxia produced by this vasoactive agent (4). In murine tu- 
mors, the bolus administration of cisplatin increases tumor blood flow 
for up to 30 min (3), a fact that may partly explain the finding that 
improved local tumor control in nonsmall cell lung tumors was seen 
only when cisplatin was administered daily before irradiation as opposed 
to other schedules ( 12). 
In a murine tumor, a mean reduction of tumor blood flow to ap- 
proximately 50% of control values was observed at 4-5 h following the 
bolus administration of tirapazamine (5). As this was only observed in 
two of four experiments, the authors cautioned that the finding was not 
conclusive proof for the vasoactivity of tirapazamine itself. Nevertheless, 
a more complete characterization of the time course with earlier time 
points could have revealed significant changes in blood Ilow in the other 
two experiments. When combined with external radiotherapy, a bolus 
dose of tirapazamine produced maximal in vivo cell killing when ad- 
ministered 30 min before radiation (2). With progressively shorter in- 
tervals, cell killing decreased until it was close to that consistent with an 
additive effect when. the two modalities were timed together. Postirra- 
diation administration of tirapazamine resulted in an increase in cell 
kill, a finding suggesting that a drug-induced increase in tumor hypoxia 
cannot be excluded. Similarly, the yet unexplained tumor-specific, 
schedule-dependent interaction between cisplatin and tirapazamine (7) 
could be a consequence of the vasoactive properties of both drugs. 
In clinical studies (6), tirapazamine was administered at a constant 
rate of infusion (3.5 mg/min) and any decrease in tumor blood flow 
could result in longer periods of hypoxia. Further investigations are par- 
ticularly necessary as another nitroxide (RB-90003X), which is also un- 
dergoing evaluation as a hypoxic cytotoxin, has been reported to reduce 
tumor blood flow (detected by laser doppler) and also produced “P mag- 
netic resonance spectra changes consistent with reduced tumor oxygen- 
ation (I). 
Considerable heterogeneity for hypoxia exists in human tumors with 
only one-third of breast tumors showing low p02 levels of between 0 
and 2.5 mm Hg (i.e., less than half-maximum radiosensitivity) (13). 
Similarly, hypoxic regions were only detected in 2 1 of 3 1 patients with 
cervical tumors who were also evaluated using computerized polaro- 
graphic electrodes (9). As there is currently no reliable noninvasive system 
to determine the extent of tumor hypoxia in individual tumors, the ben- 
efits of a hypoxic cytotoxin may be diminished if it compromises radia- 
tion-induced aerobic cell kill in tumors without significant pretreatment 
hypoxia. To a lesser extent, inappropriate timing could also compromize 
cell kill in tumors with significant numbers of hypoxic cells. 
Given the evidence for the vasoactivity of nitroxides, it is clear that 
the data from the available preclinical studies of tirapazamine cannot 
be used to predict the optimal schedule in combination with irradiation 
in clinical studies. 
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